Cardiovascular Outcomes with Nebivolol, Atenolol and Metoprolol in Patients with Hypertension: A Large, Retrospective, Propensity Score-Matched Cohort Study

Brent Egan,Alan Gradman,Sanjida Ali,Qian Li,Mehul Patel,Jan Basile

Journal of the American College of Cardiology（2017）

引用 2|浏览14

暂无评分

摘要

Introduction: β-blockers reduce risk of cardiovascular (CV) events, but comparative CV event risk between the vasodilatory β1-selective antagonist/β3 agonist nebivolol and non-vasodilatory β1-blockers atenolol and metoprolol is unknown. Objective: To compare hospitalization risk due to CV

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要